Loading news...
Acuitas Investments LLC grew its holdings in KORU Medical Systems, Inc. (NASDAQ: KRMD) by 89.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 763,088 shares of the company's stock after acquiring an additional 360,594 shares during the period. Acuitas
KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), ena.
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalberma.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights Fourth quarter 2025 net revenues gre.
KORU Medical Systems, Inc. (NASDAQ: KRMD - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and
The heavy selling pressure might have exhausted for KORU Medical Systems, Inc. (KRMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Outset Medical (NASDAQ: OM - Get Free Report) and KORU Medical Systems (NASDAQ: KRMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings. Analyst Recommendations This is a breakdown
KORU Medical Systems, Inc. (NASDAQ: KRMD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one
KORU Medical Systems, Inc. (KRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acuitas Investments LLC lessened its stake in KORU Medical Systems, Inc. (NASDAQ: KRMD) by 53.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,353 shares of the company's stock after selling 217,141 shares during the period. Acuitas Investments LLC
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy comme.
KORU Medical Systems, Inc. (KRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Earnings and Valuation This table compares
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9.
TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025. Mr. Schiller was g.
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.